Design of a recombinant immunotoxin against the human granulocyte-colony stimulating factor receptor

Area of Science:

• Biotechnology
• Molecular Biology
• Cancer Therapy

Background:

• Immunotoxins represent a novel protein therapy strategy for cancer treatment.
• Targeting overexpressed cell-surface receptors on cancer cells is key to developing effective anti-cancer agents.
• The granulocyte colony-stimulating factor (G-CSF) receptor is overexpressed in certain blood cancers like acute myeloid leukemia (AML), making it a potential therapeutic target.

Purpose of the Study:

• To design and produce a novel immunotoxin, DT-GCSF, by fusing a truncated diphtheria toxin (DT) with G-CSF.
• To evaluate the feasibility of using the G-CSF receptor as a target for immunotoxin-based cancer therapy.

Main Methods:

• Gene fragments for DT389 and G-CSF were amplified using PCR.
• A SerGly4SerMet (SG4SM) linker was employed to fuse the fragments via SOEing PCR.
• The resulting fusion gene was cloned into pET21b, transformed into E. coli BL21 (DE3), and protein expression was confirmed using SDS-PAGE and Western blotting.

Main Results:

• The DT389GCSF fusion protein was successfully designed and expressed in E. coli.
• SDS-PAGE and Western blotting confirmed the expression of the chimeric protein.
• Expression and purity rates of the DT389GCSF protein were determined to be approximately 25% and 90%, respectively.

Conclusions:

• The constructed DT-GCSF immunotoxin shows potential as a novel therapeutic agent for AML.
• Further in vitro and in vivo studies are necessary to analyze the biological activity and efficacy of this anti-AML drug candidate.